Hostname: page-component-669899f699-swprf Total loading time: 0 Render date: 2025-05-04T09:59:17.211Z Has data issue: false hasContentIssue false
  • English
  • Français

Can a medical need clause help manage the growing costs of prescription drugs in the EU?

Published online by Cambridge University Press:  03 September 2015

Eleanor Brooks  and
Robert Geyer
Eleanor Brooks*
Affiliation:
Department of Politics, Philosophy and Religion, Lancaster University, Lancaster, UK
Robert Geyer
Affiliation:
Department of Politics, Philosophy and Religion, Lancaster University, Lancaster, UK
*
*Correspondence to: Eleanor Brooks, Department of Politics, Philosophy and Religion, Lancaster University, County South Building, Lancaster LA1 4YL, UK. Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Innovation in the development of new drugs has to balance the needs of health actors and administrators, the pharmaceutical industry and patients. Differing perspectives on what constitutes an innovation, where research and development should be directed and how new drugs should be evaluated and priced cause ongoing tensions within the regulatory framework. In the current climate, where Europe’s health systems face rising demand for health services and increasingly restricted resources, the efficiency of pharmaceutical regulation and drug development is under even greater scrutiny. How can regulation foster innovation and industry growth while also serving the public health needs of society, and what is the EU’s role in pursuing this objective? Drawing on a provision which formerly existed in Norwegian pharmaceutical legislation, this article explores the potential of a medical need clause (MNC) in addressing these issues. In restricting market authorisations to those drugs that offer an added therapeutic value, might a MNC foster innovation and spending efficiency in Europe’s health systems?

Type
Articles
Information
Health Economics, Policy and Law , Volume 11 , Issue 2 , April 2016 , pp. 179 - 192
Check for updates
Copyright
© Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Abraham, J. and Lewis, G. (2000), Regulating Medicines in Europe: Competition, Expertise and Public Health, London: Routledge.Google Scholar
AIFA (Italian Medicines Agency) (2007), Criteria for ranking therapeutic innovation of new drugs, Working Group on Innovative Drugs working paper, http://www.agenziafarmaco.gov.it/allegati/integral_document.pdf [10 July 2007].Google Scholar
Andrew, M., Jøldal, B. and Tomson, G. (1995), ‘Norway’s national drug policy: its evolution and lessons for the future’, in S. Hamrell and O. Nordberg (eds), Development Dialogue: Making National Drug Policies a Development Priority, Uppsala, Sweden: The Dag Hammarskjold Centre. http://apps.who.int/medicinedocs/documents/s19175en/s19175en.pdf [13 October 2014].Google Scholar
Angell, M. (2004), The Truth about Drug Companies: How they Deceive us and What to Do About it, New York: Random House.Google Scholar
Brooks, E. and Geyer, R. (2015), ‘Whatever happened to the Norwegian Medical Need Clause? Lessons for current debates in EU pharmaceutical regulation.’ (unpublished article).Google Scholar
Buko Pharma (2013), Pharma Brief No. 8–9, Buko Pharma, Berlin, November.Google Scholar
European Commission (2007), From Assessing Innovative Value of Pharmaceuticals to Pricing and Reimbursement Decisions, Pharmaceutical Forum Working Group on Pricing and Reimbursement Brussels: European Commission.Google Scholar
European Medicines Agency (EMA) (2015), Monthly Statistics Report: December 2014, EMA/22984/2015, EMA, London, 23 January.Google Scholar
European Parliament (2011), Differences in Costs of and Access to Pharmaceutical Products in the EU, Study by the Directorate General for Internal Policies Brussels: European Parliament.Google Scholar
Garattini, J. (1997), ‘Are me-too drugs justified?’, Journal of Nephrology, 10(6): 283–294.Google Scholar
Garattini, J. and Bertele, V. (2004), ‘The role of the EMEA in regulating pharmaceutical products’, in E. Mossialos, M. Mrazek and T. Walley (eds), Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality, Berkshire: Open University Press.Google Scholar
Garattini, J. and Bertele, V. (2007), ‘Non-inferiority trials are unethical because they disregard patients’ interests’, The Lancet, 379(9602): 1875–1877.Google Scholar
Håkonsen, H., Horn, A. and Toverud, E. (2009), ‘Price control as a strategy for pharmaceutical cost containment – what has been achieved in Norway in the period 1994–2004’, Health Policy, 90: 277–285.Google Scholar
Hancher, L. (1990), ‘The European pharmaceutical market: problems of partial harmonisation’, The European Law Review, 9: 9–33.Google Scholar
Hawkes, N. (2014), ‘NICE to set out how it will judge social benefits of drugs’, British Medical Journal, 348(g370): 1–2.Google Scholar
Hervey, T. (2001), ‘Mapping the contours of European Union health law and policy’, Paper given for the ECSA Seventh Biennial International Conference, 31 May to 2 June 2001, Madison, Wisconsin.Google Scholar
Hervey, T. and McHale, J. (2004), Health Law and the European Union, Cambridge: Cambridge University Press.Google Scholar
Hollis, A. (2004), Me-too Drugs: Is There a Problem?, Copenhagen: Briefing Note, World Health Organisation.Google Scholar
International Society of Drug Bulletins (ISDB) (2001), Declaration on Therapeutic Advance in the Use of Medicines, ISDB, Paris 15–16 November.Google Scholar
Jøldal, B. (1986), ‘The evaluation and control of drugs in Norway’, International Journal of Technology Assessment in Healthcare, 2: 663–672.Google Scholar
La Revue Prescrire (2002), ‘Drugs in 2001: a number of Ruses unveiled’, Editorial in Prescrire International, 11(58): 58–60.Google Scholar
La Revue Prescrire (2012), ‘New drugs and indications in 2011’, Editorial in Prescrire International, 21(126106–110.Google Scholar
Light, D. and Lexchin, J. (2012), ‘Pharmaceutical research and development: what do we get for all that money?’, British Medical Journal, 344(e4348): 1–5.Google Scholar
Light, D., Lexchin, J. and Darrow, J. (2013), ‘Institutional corruption of pharmaceuticals and the myth of safe and effective drugs’, Journal of Law, Medicine and Ethics, 14(3): 2–12.Google Scholar
Lu, Y., Hernandez, P., Abegunde, D. and Edejer, T. (2011), The World Medicines Situation 2011: Medical Expenditures, Geneva: World Health Organisation.Google Scholar
Morgan, S., Bassett, K., Wright, J., Evans, R., Barer, M., Caetano, P. and Black, C. (2005), ‘Breakthrough drugs and growth in expenditure on prescription drugs in Canada’, British Medical Journal, 331(815): 1–2.CrossRefGoogle ScholarPubMed
Nathan, C. (2007), ‘Aligning pharmaceutical innovation with medical need’, Nature Medicine, 13(3): 304–308.Google Scholar
Norris, P. (1998), ‘The impact of European harmonisation on Norwegian drug policy’, Health Policy, 43: 65–81.CrossRefGoogle ScholarPubMed
OECD (2011), ‘Pharmaceutical expenditure’, in OECD Health at a Glance 2011: OECD Indicators, Paris: OECD Publishers, 154–156.Google Scholar
OECD (2013), ‘Pharmaceutical expenditure’, in OECD Health at a Glance 2013: OECD Indicators, Paris: OECD Publishers, 160–162.Google Scholar
Paris, V. and Belloni, A. (2013), ‘Value in Pharmaceutical Pricing’, OECD Health Working Papers, Number 63 [13 October 2014].Google Scholar
Raftery, J. (2013), ‘Value-based pricing: can it work?’, British Medical Journal, 347(f5941): 1–4.CrossRefGoogle ScholarPubMed
Raftery, J. (2014), ‘Sofosbufir for hepatitis C – moving to country specific prices’, British Medical Journal Blog, published online 20 August 2014.Google Scholar
Simon, R. (2000), ‘Are placebo-controlled clinical trials ethical or needed when alternative treatment exists?’, Annals of Internal Medicine, 133(6): 474–475.Google Scholar
Vitry, A., Shin, N. and Vitre, P. (2013), ‘Assessment of the therapeutic value of new medicines marketed in Australia’, Journal of Pharmaceutical Policy and Practice, 6(2): 1–6.Google ScholarPubMed
Wemos (2013), The clinical trials industry in South Africa: ethics, rules and realities, http://www.wemos.nl/files/Documenten%20Informatief/Bestanden%20voor%20%27Medicijnen%27/Clinical_Trials_Industry_South_Africa_2013_v3.pdf [13 October 2014].Google Scholar
Wieseler, B. (2011), ‘How, and on whose behalf, should the ‘added therapeutic value’ of a new drug be assessed?’ Pilule d’Or Prescrire, conference debate, http://www.prescrire.org/Docu/Archive/docus/WieselerENPiluleOrPrescrire2011.pdf [13 October 2014].Google Scholar
Wilson, J. (1980), The Politics of Regulation, New York: Basic Books.Google Scholar
Wise, J. (2013), ‘NHS spending on drugs is frozen for two years under price deal’, British Medical Journal, 347(f6731): 1.Google Scholar